Download PDF
Semin Respir Crit Care Med 2017; 38(05): 606-618
DOI: 10.1055/s-0037-1606317
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies

Manreet Kanwar
1   Division of Cardiology, Allegheny General Hospital, Pittsburgh, Pennsylvania
,
Amresh Raina
1   Division of Cardiology, Allegheny General Hospital, Pittsburgh, Pennsylvania
,
Michael Passineau
1   Division of Cardiology, Allegheny General Hospital, Pittsburgh, Pennsylvania
,
Raymond Benza
1   Division of Cardiology, Allegheny General Hospital, Pittsburgh, Pennsylvania
› Author Affiliations
Further Information

Publication History

Publication Date:
15 October 2017 (online)

    Permissions and Reprints

Abstract

The field of pulmonary arterial hypertension (PAH) has seen substantial changes in the epidemiology, associated comorbidities, treatment algorithms, and prognosis in the past decade. Specifically for idiopathic PAH (IPAH), there has been a noted increase in the age of initial diagnosis. Increasing focus is being placed on appropriate categorization of patients with PAH, both in terms of diagnosis and individualized risk stratification. This is especially relevant given that patients being diagnosed with incident IPAH are now older and with multiple comorbidities, putting them at a higher risk of being mislabeled as PAH. The biggest impact has been seen in the number of pharmaceutical options available for these patients, resulting in improvement in both short- and long-term outcomes. In addition, there has been a shift in the treatment approach to the early use of combination therapies in PAH, since it has been demonstrated to improve clinical outcomes. Novel therapies are in the pipeline for patients with IPAH to impact both the morbidity and mortality of this deadly disease.

Keywords

idiopathic pulmonary arterial hypertension - pulmonary vascular resistance - morbidity
 

  • References

  • 1 Galiè N, Humbert M, Vachiery JL. , et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (01) 67-119
    CrossrefPubMedGoogle Scholar
  • 2 Simonneau G, Gatzoulis MA, Adatia I. , et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D34-D41
    CrossrefPubMedGoogle Scholar
  • 3 Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30 (01) 104-109
    CrossrefPubMedGoogle Scholar
  • 4 Humbert M, Sitbon O, Chaouat A. , et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173 (09) 1023-1030
    CrossrefPubMedGoogle Scholar
  • 5 Ling Y, Johnson MK, Kiely DG. , et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186 (08) 790-796
    CrossrefPubMedGoogle Scholar
  • 6 Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010; 96 (17) 1401-1406
    CrossrefPubMedGoogle Scholar
  • 7 Badesch DB, Raskob GE, Elliott CG. , et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 2010; 137 (02) 376-387
    CrossrefPubMedGoogle Scholar
  • 8 Rich S, Dantzker DR, Ayres SM. , et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107 (02) 216-223
    CrossrefPubMedGoogle Scholar
  • 9 McGoon MD, Benza RL, Escribano-Subias P. , et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62 (25, Suppl): D51-D59
    CrossrefPubMedGoogle Scholar
  • 10 Humbert M, Sitbon O, Chaouat A. , et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122 (02) 156-163
    CrossrefPubMedGoogle Scholar
  • 11 Hoeper MM, Huscher D, Ghofrani HA. , et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168 (02) 871-880
    CrossrefPubMedGoogle Scholar
  • 12 Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest 2013; 144 (01) 169-176
    CrossrefPubMedGoogle Scholar
  • 13 Dorfmüller P, Humbert M. Progress in pulmonary arterial hypertension pathology: relighting a torch inside the tunnel. Am J Respir Crit Care Med 2012; 186 (03) 210-212
    CrossrefPubMedGoogle Scholar
  • 14 Dai Z, Zhao YY. Discovery of a murine model of clinical PAH: mission impossible?. Trends Cardiovasc Med 2017; 27 (04) 229-236
    CrossrefPubMedGoogle Scholar
  • 15 Ryan JJ, Marsboom G, Archer SL. Rodent models of group 1 pulmonary hypertension. Handb Exp Pharmacol 2013; 218: 105-149
    PubMedGoogle Scholar
  • 16 Galiè N, Barberà JA, Frost AE. , et al; AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373 (09) 834-844
    CrossrefPubMedGoogle Scholar
  • 17 Rothman A, Mann DM, House MT. , et al. Transvenous procurement of pulmonary artery smooth muscle and endothelial cells using a novel endoarterial biopsy catheter in a canine model. J Am Coll Cardiol 1996; 27 (01) 218-224
    PubMedGoogle Scholar
  • 18 Sa S, Gu M, Chapperll J. , et al. Induced pluripotent stem cell model of pulmonary arterial hypertension reveals novel gene expression and patient specificity. Am J Respir Crit Care Me 2017; 195 (07) 930-941
    PubMedGoogle Scholar
  • 19 Benza RL, Williams G, Wu C. , et al. In situ expression of Bcl-2 in pulmonary artery endothelial cells associates with pulmonary arterial hypertension relative to heart failure with preserved ejection fraction. Pulm Circ 2016; 6 (04) 551-556
    CrossrefPubMedGoogle Scholar
  • 20 Tuder RM, Archer SL, Dorfmüller P. , et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D4-D12
    CrossrefPubMedGoogle Scholar
  • 21 Lane KB, Machado RD, Pauciulo MW. , et al; International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26 (01) 81-84
    CrossrefPubMedGoogle Scholar
  • 22 Deng Z, Morse JH, Slager SL. , et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67 (03) 737-744
    CrossrefPubMedGoogle Scholar
  • 23 Atkinson C, Stewart S, Upton PD. , et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002; 105 (14) 1672-1678
    CrossrefPubMedGoogle Scholar
  • 24 Austin ED, Cogan JD, West JD. , et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009; 34 (05) 1093-1099
    CrossrefPubMedGoogle Scholar
  • 25 Austin ED, Hamid R, Hemnes AR. , et al. BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ 2012; 3 (01) 6
    CrossrefPubMedGoogle Scholar
  • 26 Ventetuolo CE, Mitra N, Wan F. , et al. Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. Eur Respir J 2016; 47 (02) 553-563
    CrossrefPubMedGoogle Scholar
  • 27 Galiè N, Humbert M, Vachiery JL. , et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46 (04) 903-975
    CrossrefPubMedGoogle Scholar
  • 28 McLaughlin VV, Archer SL, Badesch DB. , et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53 (17) 1573-1619
    CrossrefPubMedGoogle Scholar
  • 29 Bossone E, D'Andrea A, D'Alto M. , et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr 2013; 26 (01) 1-14
    CrossrefPubMedGoogle Scholar
  • 30 Melenovsky V, Borlaug BA, Rosen B. , et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007; 49 (02) 198-207
    CrossrefPubMedGoogle Scholar
  • 31 Nagueh SF, Appleton CP, Gillebert TC. , et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10 (02) 165-193
    PubMedGoogle Scholar
  • 32 Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002; 90 (12) 1284-1289
    CrossrefPubMedGoogle Scholar
  • 33 Caballero L, Kou S, Dulgheru R. , et al. Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE study. Eur Heart J Cardiovasc Imaging 2015; 16 (09) 1031-1041
    PubMedGoogle Scholar
  • 34 Nagueh SF, Smiseth OA, Appleton CP. , et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016; 17 (12) 1321-1360
    CrossrefPubMedGoogle Scholar
  • 35 Arkles JS, Opotowsky AR, Ojeda J. , et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med 2011; 183 (02) 268-276
    CrossrefPubMedGoogle Scholar
  • 36 Opotowsky AR, Ojeda J, Rogers F. , et al. A simple echocardiographic prediction rule for hemodynamics in pulmonary hypertension. Circ Cardiovasc Imaging 2012; 5 (06) 765-775
    CrossrefPubMedGoogle Scholar
  • 37 Tossavainen E, Söderberg S, Grönlund C, Gonzalez M, Henein MY, Lindqvist P. Pulmonary artery acceleration time in identifying pulmonary hypertension patients with raised pulmonary vascular resistance. Eur Heart J Cardiovasc Imaging 2013; 14 (09) 890-897
    CrossrefPubMedGoogle Scholar
  • 38 Abbas AE, Franey LM, Marwick T. , et al. Noninvasive assessment of pulmonary vascular resistance by Doppler echocardiography. J Am Soc Echocardiogr 2013; 26 (10) 1170-1177
    CrossrefPubMedGoogle Scholar
  • 39 Dahiya A, Vollbon W, Jellis C, Prior D, Wahi S, Marwick T. Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. Heart 2010; 96 (24) 2005-2009
    CrossrefPubMedGoogle Scholar
  • 40 Opotowsky AR, Clair M, Afilalo J. , et al. A simple echocardiographic method to estimate pulmonary vascular resistance. Am J Cardiol 2013; 112 (06) 873-882
    CrossrefPubMedGoogle Scholar
  • 41 Dadfarmay S, Berkowitz R, Kim B, Manchikalapudi RB. Differentiating pulmonary arterial and pulmonary venous hypertension and the implications for therapy. Congest Heart Fail 2010; 16 (06) 287-291
    CrossrefPubMedGoogle Scholar
  • 42 Zakir RM, Al-Dehneh A, Maher J, Saric M, Berkowitz RL. Right ventricular failure in patients with preserved ejection fraction and diastolic dysfunction: an underrecognized clinical entity. Congest Heart Fail 2007; 13 (03) 164-169
    CrossrefPubMedGoogle Scholar
  • 43 van de Veerdonk MC, Kind T, Marcus JT. , et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011; 58 (24) 2511-2519
    CrossrefPubMedGoogle Scholar
  • 44 Brewis MJ, Bellofiore A, Vanderpool RR. , et al. Imaging right ventricular function to predict outcome in pulmonary arterial hypertension. Int J Cardiol 2016; 218: 206-211
    CrossrefPubMedGoogle Scholar
  • 45 Sanz J, García-Alvarez A, Fernández-Friera L. , et al. Right ventriculo-arterial coupling in pulmonary hypertension: a magnetic resonance study. Heart 2012; 98 (03) 238-243
    CrossrefPubMedGoogle Scholar
  • 46 Truong U, Patel S, Kheyfets V. , et al. Non-invasive determination by cardiovascular magnetic resonance of right ventricular-vascular coupling in children and adolescents with pulmonary hypertension. J Cardiovasc Magn Reson 2015; 17: 81
    CrossrefPubMedGoogle Scholar
  • 47 Blyth KG, Groenning BA, Martin TN. , et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J 2005; 26 (19) 1993-1999
    CrossrefPubMedGoogle Scholar
  • 48 McCann GP, Beek AM, Vonk-Noordegraaf A, van Rossum AC. Delayed contrast-enhanced magnetic resonance imaging in pulmonary arterial hypertension. Circulation 2005; 112 (16) e268
    CrossrefPubMedGoogle Scholar
  • 49 Sanz J, Dellegrottaglie S, Kariisa M. , et al. Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension. Am J Cardiol 2007; 100 (04) 731-735
    CrossrefPubMedGoogle Scholar
  • 50 D'Alonzo GE, Barst RJ, Ayres SM. , et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115 (05) 343-349
    CrossrefPubMedGoogle Scholar
  • 51 Benza RL, Miller DP, Gomberg-Maitland M. , et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122 (02) 164-172
    CrossrefPubMedGoogle Scholar
  • 52 Heresi GA, Tang WH, Aytekin M, Hammel J, Hazen SL, Dweik RA. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. Eur Respir J 2012; 39 (04) 939-944
    CrossrefPubMedGoogle Scholar
  • 53 Dhaun N, Vachiery JL, Benza RL. , et al. Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations. J Heart Lung Transplant 2014; 33 (05) 521-527
    CrossrefPubMedGoogle Scholar
  • 54 Carlomagno G, Messalli G, Melillo RM. , et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol 2013; 168 (02) 1545-1547
    CrossrefPubMedGoogle Scholar
  • 55 Zheng YG, Yang T, He JG. , et al. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Clin Cardiol 2014; 37 (06) 365-370
    CrossrefPubMedGoogle Scholar
  • 56 Fijalkowska A, Kurzyna M, Torbicki A. , et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129 (05) 1313-1321
    CrossrefPubMedGoogle Scholar
  • 57 Mauritz GJ, Rizopoulos D, Groepenhoff H. , et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2011; 108 (11) 1645-1650
    CrossrefPubMedGoogle Scholar
  • 58 Nagaya N, Nishikimi T, Uematsu M. , et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102 (08) 865-870
    CrossrefPubMedGoogle Scholar
  • 59 Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167 (04) 580-586
    CrossrefPubMedGoogle Scholar
  • 60 McLaughlin VV, Sitbon O, Badesch DB. , et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25 (02) 244-249
    CrossrefPubMedGoogle Scholar
  • 61 Raymond RJ, Hinderliter AL, Willis PW. , et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39 (07) 1214-1219
    CrossrefPubMedGoogle Scholar
  • 62 Forfia PR, Fisher MR, Mathai SC. , et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174 (09) 1034-1041
    CrossrefPubMedGoogle Scholar
  • 63 Badagliacca R, Papa S, Valli G. , et al. Echocardiography combined with cardiopulmonary exercise testing for the prediction of outcome in idiopathic pulmonary arterial hypertension. Chest 2016; 150 (06) 1313-1322
    CrossrefPubMedGoogle Scholar
  • 64 Courand PY, Pina Jomir G, Khouatra C. , et al. Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension. Eur Respir J 2015; 45 (01) 139-149
    CrossrefPubMedGoogle Scholar
  • 65 McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106 (12) 1477-1482
    CrossrefPubMedGoogle Scholar
  • 66 Sitbon O, Humbert M, Nunes H. , et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40 (04) 780-788
    CrossrefPubMedGoogle Scholar
  • 67 Benza RL, Gomberg-Maitland M, Miller DP. , et al. The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012; 141 (02) 354-362
    CrossrefPubMedGoogle Scholar
  • 68 Benza RL, Miller DP, Foreman AJ. , et al. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant 2015; 34 (03) 356-361
    CrossrefPubMedGoogle Scholar
  • 69 Kanwar MK, Thenappan T, Vachiéry JL. Update in treatment options in pulmonary hypertension. J Heart Lung Transplant 2016; 35 (06) 695-703
    CrossrefPubMedGoogle Scholar
  • 70 Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70 (04) 580-587
    CrossrefPubMedGoogle Scholar
  • 71 Olsson KM, Delcroix M, Ghofrani HA. , et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129 (01) 57-65
    CrossrefPubMedGoogle Scholar
  • 72 Kawut SM, Bagiella E, Lederer DJ. , et al; ASA-STAT Study Group. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011; 123 (25) 2985-2993
    CrossrefPubMedGoogle Scholar
  • 73 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327 (02) 76-81
    CrossrefPubMedGoogle Scholar
  • 74 Sitbon O, Humbert M, Jaïs X. , et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111 (23) 3105-3111
    CrossrefPubMedGoogle Scholar
  • 75 Rhee RL, Gabler NB, Sangani S, Praestgaard A, Merkel PA, Kawut SM. Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192 (09) 1111-1117
    CrossrefPubMedGoogle Scholar
  • 76 Galiè N, Olschewski H, Oudiz RJ. , et al; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117 (23) 3010-3019
    CrossrefPubMedGoogle Scholar
  • 77 Rubin LJ, Badesch DB, Barst RJ. , et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 (12) 896-903
    CrossrefPubMedGoogle Scholar
  • 78 Humbert M, Barst RJ, Robbins IM. , et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24 (03) 353-359
    CrossrefPubMedGoogle Scholar
  • 79 Galiè N, Rubin Lj, Hoeper M. , et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371 (9630): 2093-2100
    CrossrefPubMedGoogle Scholar
  • 80 Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24 (06) 1007-1010
    CrossrefPubMedGoogle Scholar
  • 81 Hoeper MM, Leuchte H, Halank M. , et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28 (04) 691-694
    CrossrefPubMedGoogle Scholar
  • 82 Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27 (05) 589-595
    CrossrefPubMedGoogle Scholar
  • 83 Pulido T, Adzerikho I, Channick RN. , et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369 (09) 809-818
    CrossrefPubMedGoogle Scholar
  • 84 Jing ZC, Yu ZX, Shen JY. , et al; Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011; 183 (12) 1723-1729
    CrossrefPubMedGoogle Scholar
  • 85 Galiè N, Brundage BH, Ghofrani HA. , et al; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119 (22) 2894-2903
    CrossrefPubMedGoogle Scholar
  • 86 Galiè N, Ghofrani HA, Torbicki A. , et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353 (20) 2148-2157
    CrossrefPubMedGoogle Scholar
  • 87 Ghofrani HA, Galiè N, Grimminger F. , et al; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369 (04) 330-340
    CrossrefPubMedGoogle Scholar
  • 88 Sitbon O, McLaughlin VV, Badesch DB. , et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60 (12) 1025-1030
    CrossrefPubMedGoogle Scholar
  • 89 Barst RJ, Rubin LJ, Long WA. , et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334 (05) 296-301
    CrossrefPubMedGoogle Scholar
  • 90 Simonneau G, Barst RJ, Galie N. , et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (06) 800-804
    CrossrefPubMedGoogle Scholar
  • 91 Sitbon O, Channick R, Chin KM. , et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2015; 373: 2522-2533
    CrossrefPubMedGoogle Scholar
  • 92 Toyoda Y, Thacker J, Santos R. , et al. Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. Ann Thorac Surg 2008; 86 (04) 1116-1122
    CrossrefPubMedGoogle Scholar
  • 93 Sitbon O, Sattler C, Bertoletti L. , et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J 2016; 47 (06) 1727-1736
    CrossrefPubMedGoogle Scholar
  • 94 Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest 2012; 142 (02) 448-456
    CrossrefPubMedGoogle Scholar
  • 95 Kawut SM, Taichman DB, Ahya VN. , et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11 (09) 1107-1111
    CrossrefPubMedGoogle Scholar
  • 96 Rosenzweig EB, Morse JH, Knowles JA. , et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 2008; 27 (06) 668-674
    CrossrefPubMedGoogle Scholar
  • 97 Sztrymf B, Coulet F, Girerd B. , et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008; 177 (12) 1377-1383
    CrossrefPubMedGoogle Scholar
  • 98 Halliday SJ, Hemnes AR, Robbins IM. , et al. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the “classic” responders. J Heart Lung Transplant 2015; 34 (03) 312-318
    CrossrefPubMedGoogle Scholar
  • 99 Sitbon O, Humbert M, Jagot JL. , et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12 (02) 265-270
    CrossrefPubMedGoogle Scholar
  • 100 Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 2010; 104 (04) 481-496
    CrossrefPubMedGoogle Scholar
  • 101 Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35 (05) 1079-1087
    CrossrefPubMedGoogle Scholar
  • 102 Frost AE, Badesch DB, Barst RJ. , et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 2011; 139 (01) 128-137
    CrossrefPubMedGoogle Scholar
  • 103 Escribano-Subias P, Blanco I, López-Meseguer M. , et al; REHAP investigators. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J 2012; 40 (03) 596-603
    CrossrefPubMedGoogle Scholar
  • 104 Jia WB, Jiang X, Zuo XR. , et al. [Clinical characteristics of 161 Chinese patients with idiopathic pulmonary arterial hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi 2012; 40 (08) 652-656
    PubMedGoogle Scholar
  • 105 Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 2011; 139 (06) 1285-1293
    CrossrefPubMedGoogle Scholar